###### CR Governance\n\nOur corporate responsibility initiatives are driven by our Chief Executive Officer and executive-level Corporate Responsibility Steering Committee (CR Committee). The CR Committee consists of senior leaders in key functions across the company, including Legal, Finance, Investor Relations, Human Resources, Research and Development, Manufacturing, Commercial, Compliance and Corporate Affairs. In 2023, we expanded our CR Committee to include a broader cross-section of senior leaders to ensure we continue to develop the right programs, policies and systems to oversee ethical and sustainable operations across our business.\n\nOur Board of Directors, specifically the Nominating, Governance and Review Committee, has oversight of our overall CR strategy and material ESG risks and opportunities as outlined in the Committee's charter. The Board receives updates at least once annually and is engaged on specific topics as needed.\n\nOur approach to CR strategy and disclosure is informed by our stakeholders and third-party frameworks such as the Sustainability Accounting Standards Board (SASB) Health Care – Biotechnology and Pharmaceuticals Standard and the Task Force on ClimateRelated Financial Disclosures (TCFD). Our SASB Index and TCFD reporting are included in the Appendix of this report.\n\n###### Public Policy and Political Contributions\n\nWe established a formal government affairs and public policy function in 2024. As our approach evolves, we are committed to transparency and we plan to make required lobbying disclosures, trade association memberships and contributions publicly available.\n\nIonis does not use corporate resources, either directly or indirectly, to contribute to or support any election-related activity, including contributions to candidates, political parties or committees, ballot initiatives or measures or other political entities.